Teva Pharmaceutical Industries (NYSE:TEVA) has officially appointed Matthew Shields as the new Executive Vice President of Teva Global Operations (TGO), effective June 3, 2024.

Shields will be stepping into the role previously held by Eric Drapé, who departs after a commendable 11-year tenure with the company, including over four years in his recent executive position.

Matthew Shields joins Teva with an extensive background spanning over 25 years in the global biopharmaceutical and animal health sectors.

As a seasoned engineer, Shields has acquired comprehensive expertise across all phases of manufacturing and supply chain management.

His most recent role was as Senior Vice President for Animal Health Manufacturing at Merck. There, he managed a wide range of responsibilities from manufacturing to procurement and process development.

As part of Teva’s Executive Leadership Team, Shields will report directly to Richard Francis, President and CEO of Teva, and will be based at the company’s U.S. headquarters in Parsippany, New Jersey.